Current therapeutic options in advanced melanoma include PD-1 inhibitors associated or not with CTLA-4 or lymphocyte-activating gene (LAG)-3 inhibitors and in cases of BRAF V600E/K mutated BRAF inhibitors, called targeted therapy [11,47]. This evidence concerns the gene BRAF and melanoma.